Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 10/2009

01-10-2009 | Review

A systematic review of humoral immune responses against tumor antigens

Authors: Miriam Reuschenbach, Magnus von Knebel Doeberitz, Nicolas Wentzensen

Published in: Cancer Immunology, Immunotherapy | Issue 10/2009

Login to get access

Abstract

This review summarizes studies on humoral immune responses against tumor-associated antigens (TAAs) with a focus on antibody frequencies and the potential diagnostic, prognostic, and etiologic relevance of antibodies against TAAs. We performed a systematic literature search in Medline and identified 3,619 articles on humoral immune responses and TAAs. In 145 studies, meeting the inclusion criteria, humoral immune responses in cancer patients have been analyzed against over 100 different TAAs. The most frequently analyzed antigens were p53, MUC1, NY-ESO-1, c-myc, survivin, p62, cyclin B1, and Her2/neu. Antibodies against these TAAs were detected in 0–69% (median 14%) of analyzed tumor patients. Antibody frequencies were generally very low in healthy individuals, with the exception of few TAAs, especially MUC1. For several TAAs, including p53, Her2/neu, and NY-ESO-1, higher antibody frequencies were reported when tumors expressed the respective TAA. Antibodies against MUC1 were associated with a favorable prognosis while antibodies against p53 were associated with poor disease outcome. These data suggest different functional roles of endogenous antibodies against TAAs. Although data on prediagnostic antibody levels are scarce and antibody frequencies for most TAAs are at levels precluding use in diagnostic assays for cancer early detection, there is some promising data on achieving higher sensitivity for cancer detection using panels of TAAs.
Appendix
Available only for authorised users
Literature
1.
2.
Fonseca C, Dranoff G (2008) Capitalizing on the immunogenicity of dying tumor cells. Clin Cancer Res 14:1603–1608PubMedCrossRef
3.
Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2:293–299PubMedCrossRef
4.
Turk MJ, Wolchok JD, Guevara-Patino JA et al (2002) Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol Rev 188:122–135PubMedCrossRef
5.
6.
Houghton AN (1994) Cancer antigens: immune recognition of self and altered self. J Exp Med 180:1–4PubMedCrossRef
7.
Jäger E, Jäger D, Knuth A (2003) Antigen-specific immunotherapy and cancer vaccines. Int J Cancer 106:817–820PubMedCrossRef
8.
Renkvist N, Castelli C, Robbins PF et al (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50:3–15PubMedCrossRef
9.
10.
Rescigno M, Avogadri F, Curigliano G (2007) Challenges and prospects of immunotherapy as cancer treatment. Biochim Biophys Acta 1776:108–123PubMed
11.
Himoto T, Kuriyama S, Zhang JY et al (2005) Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma. Int J Oncol 27:1079–1085PubMed
12.
Zhang JY, Casiano CA, Peng XX et al (2003) Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 12:136–143PubMed
13.
Zhang JY, Megliorino R, Peng XX et al (2007) Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol 46:107–114PubMedCrossRef
14.
Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al (2000) Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18:574–583
15.
Croce MV, Isla-Larrain MT, Capafons A et al (2001) Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women. Breast Cancer Res Treat 69:1–11PubMedCrossRef
16.
Kurtenkov O, Klaamas K, Rittenhouse-Olson K et al (2005) IgG immune response to tumor-associated carbohydrate antigens (TF, Tn, alphaGal) in patients with breast cancer: impact of neoadjuvant chemotherapy and relation to the survival. Exp Oncol 27:136–140PubMed
17.
Kurtenkov O, Klaamas K, Mensdorff-Pouilly S et al (2007) Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. Acta Oncol 46:316–323PubMedCrossRef
18.
Hamanaka Y, Suehiro Y, Fukui M et al (2003) Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 103:97–100PubMedCrossRef
19.
Ralhan R, Nath N, Agarwal S et al (1998) Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Clin Cancer Res 4:2147–2152PubMed
20.
Looi K, Megliorino R, Shi FD et al (2006) Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep 16:1105–1110PubMed
21.
Koziol JA, Zhang JY, Casiano CA et al (2003) Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 9:5120–5126PubMed
22.
Ralhan R, Arora S, Chattopadhyay TK et al (2000) Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int J Cancer 85:791–795PubMedCrossRef
23.
Richards ER, Devine PL, Quin RJ et al (1998) Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 46:245–252PubMedCrossRef
24.
Graves CR, Robertson JF, Murray A et al (2005) Malignancy-induced autoimmunity to MUC1: initial antibody characterization. J Pept Res 66:357–363PubMedCrossRef
25.
Green JA, Mudenda B, Jenkins J et al (1994) Serum p53 auto-antibodies: incidence in familial breast cancer. Eur J Cancer 30A:580–584PubMedCrossRef
26.
Davidoff AM, Iglehart JD, Marks JR (1992) Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89:3439–3442PubMedCrossRef
27.
Komiya T, Hirashima T, Takada M et al (1997) Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung. Anticancer Res 17:3721–3724PubMed
28.
Kressner U, Glimelius B, Bergstrom R et al (1998) Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer 77:1848–1851PubMed
29.
Hammel P, Leroy-Viard K, Chaumette MT et al (1999) Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. Int J Cancer 81:712–718PubMedCrossRef
30.
Bourhis J, Lubin R, Roche B et al (1996) Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 88:1228–1233PubMedCrossRef
31.
Lechpammer M, Lukac J, Lechpammer S et al (2004) Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis 19:114–120PubMedCrossRef
32.
Soussi T (2000) p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60:1777–1788PubMed
33.
Jäger E, Stockert E, Zidianakis Z et al (1999) Humoral immune responses of cancer patients against “Cancer-Testis” antigen NY-ESO-1: correlation with clinical events. Int J Cancer 84:506–510PubMedCrossRef
34.
Maio M, Coral S, Sigalotti L et al (2003) Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J Clin Endocrinol Metab 88:748–754PubMedCrossRef
35.
Stockert E, Jäger E, Chen YT et al (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187:1349–1354PubMedCrossRef
36.
Goodell V, Waisman J, Salazar LG et al (2008) Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther 7:449–454PubMedCrossRef
37.
Karsten U, Mensdorff-Pouilly S, Goletz S (2005) What makes MUC1 a tumor antigen? Tumour Biol 26:217–220PubMedCrossRef
38.
Reuschenbach M, Waterboer T, Wallin KL et al (2008) Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers. Int J Cancer 123:2626–2631PubMedCrossRef
39.
Akcakanat A, Kanda T, Koyama Y et al (2004) NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol 54:95–100PubMedCrossRef
40.
Fossa A, Berner A, Sophie DF et al (2004) NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 59:440–447PubMedCrossRef
41.
Wadle A, Kubuschok B, Imig J et al (2006) Serological immune response to cancer testis antigens in patients with pancreatic cancer. Int J Cancer 119:117–125PubMedCrossRef
42.
Chang JT, Wong FH, Liao CT et al (2004) Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients. Clin Chem 50:1261–1264PubMedCrossRef
43.
Fishman P, Merimski O, Baharav E et al (1997) Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Cancer 79:1461–1464PubMedCrossRef
44.
Disis ML, Pupa SM, Gralow JR et al (1997) High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15:3363–3367PubMed
45.
Nakamura H, Hinoda Y, Nakagawa N et al (1998) Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J Gastroenterol 33:354–361PubMedCrossRef
46.
Traina A, Agostara B, Marasa L et al (2006) HER2/neu expression in relation to clinicopathologic features of breast cancer patients. Ann N Y Acad Sci 1089:159–167PubMedCrossRef
47.
Ferretti G, Felici A, Papaldo P et al (2007) HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 19:56–62PubMedCrossRef
48.
Nesterova M, Johnson N, Cheadle C et al (2006) Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 1762:398–403PubMed
49.
Kim JH, Herlyn D, Wong KK et al (2003) Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 9:4782–4791PubMed
50.
Qin S, Qiu W, Ehrlich JR et al (2006) Development of a “reverse capture” autoantibody microarray for studies of antigen-autoantibody profiling. Proteomics 6:3199–3209PubMedCrossRef
51.
Philip R, Murthy S, Krakover J et al (2007) Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J Proteome Res 6:2509–2517PubMedCrossRef
52.
Lu H, Goodell V, Disis ML (2008) Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 7:2168CrossRef
53.
Ran Y, Hu H, Zhou Z et al (2008) Profiling tumor-associated autoantibodies for the detection of colon cancer. Clin Cancer Res 14:2696–2700PubMedCrossRef
54.
Abendstein B, Marth C, Müller-Holzner E et al (2000) Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer 88:1432–1437PubMedCrossRef
55.
Mayerhofer K, Tempfer C, Kucera E et al (1999) Humoral p53 antibody response is a prognostic parameter in ovarian cancer. Anticancer Res 19:875–878PubMed
56.
Volkmann M, Sinn HP, Gaugel D et al (2002) Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression. Oncology 63:297–305PubMedCrossRef
57.
Tang R, Ko MC, Wang JY et al (2001) Humoral response to p53 in human colorectal tumors: a prospective study of 1, 209 patients. Int J Cancer 94:859–863PubMedCrossRef
58.
Lai CL, Tsai CM, Tsai TT et al (1998) Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Clin Cancer Res 4:3025–3030PubMed
59.
Qiu LL, Hua PY, Ye LL et al (2007) The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China. Cancer Detect Prev 31:45–49PubMedCrossRef
60.
Sangrajrang S, Arpornwirat W, Cheirsilpa A et al (2003) Serum p53 antibodies in correlation to other biological parameters of breast cancer. Cancer Detect Prev 27:182–186PubMedCrossRef
61.
Jezersek B, Rudolf Z, Novakovic S (2001) The circulating auto-antibodies to p53 protein in the follow-up of lymphoma patients. Oncol Rep 8:77–81PubMed
62.
Shimada H, Takeda A, Arima M et al (2000) Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 89:1677–1683PubMedCrossRef
63.
Vogl FD, Stickeler E, Weyermann M et al (1999) p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells. Oncology 57:324–329PubMedCrossRef
64.
Scott N, Sagar P, Stewart J et al (1991) p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 63:317–319PubMed
65.
Qin Z, Richter G, Schüler T et al (1998) B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 4:627–630PubMedCrossRef
66.
Gumus E, Erdamar S, Demirel G et al (2004) Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. Int J Urol 11:1070–1077PubMedCrossRef
67.
Manson LA (1991) Does antibody-dependent epitope masking permit progressive tumour growth in the face of cell-mediated cytotoxicity? Immunol Today 12:352–355PubMedCrossRef
68.
Tan TT, Coussens LM (2007) Humoral immunity, inflammation and cancer. Curr Opin Immunol 19:209–216PubMedCrossRef
69.
Imai H, Ochs RL, Kiyosawa K et al (1992) Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol 140:859–870PubMed
70.
Trivers GE, Cawley HL, DeBenedetti VM et al (1995) Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 87:1400–1407PubMedCrossRef
71.
Lubin R, Schlichtholz B, Teillaud JL et al (1995) p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res 1:1463–1469PubMed
72.
Schlichtholz B, Legros Y, Gillet D et al (1992) The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52:6380–6384PubMed
73.
Lubin R, Zalcman G, Bouchet L et al (1995) Serum p53 antibodies as early markers of lung cancer. Nat Med 1:701–702PubMedCrossRef
74.
Schlichtholz B, Tredaniel J, Lubin R et al (1994) Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 69:809–816PubMed
75.
Angelopoulou K, Diamandis EP, Sutherland DJ et al (1994) Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58:480–487PubMedCrossRef
76.
Hammel P, Boissier B, Chaumette MT et al (1997) Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 40:356–361PubMed
77.
Korangy F, Ormandy LA, Bleck JS et al (2004) Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10:4332–4341PubMedCrossRef
78.
Yonezawa S, Goto M, Yamada N et al (2008) Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics 8:3329–3341PubMedCrossRef
79.
Parmigiani RB, Bettoni F, Grosso DM et al (2008) Antibodies against the cancer-testis antigen CTSP-1 are frequently found in prostate cancer patients and are an independent prognostic factor for biochemical-recurrence. Int J Cancer 122:2385–2390PubMedCrossRef
80.
Bachelot T, Ratel D, Menetrier-Caux C et al (2006) Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. Br J Cancer 94:1066–1070PubMedCrossRef
81.
Hirasawa Y, Kohno N, Yokoyama A et al (2000) Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 161:589–594PubMed
82.
Shimada H, Kuboshima M, Shiratori T et al (2007) Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol 30:97–103PubMed
83.
Boon T, van der BP (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725–729PubMedCrossRef
84.
Finn OJ (2007) Human tumor immunology at the molecular divide. J Immunol 178:2615–2616PubMed
85.
Wesseling J, van der Valk SW, Hilkens J (1996) A mechanism for inhibition of E-cadherin-mediated cell–cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 7:565–577PubMed
86.
Agrawal B, Krantz MJ, Reddish MA et al (1998) Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 4:43–49PubMedCrossRef
87.
Gourevitch MM, Mensdorff-Pouilly S, Litvinov SV et al (1995) Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br J Cancer 72:934–938PubMed
88.
Cramer DW, Titus-Ernstoff L, McKolanis JR et al (2005) Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 14:1125–1131PubMedCrossRef
89.
Menard S, Casalini P, Campiglio M et al (2004) Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 61:2965–2978PubMedCrossRef
90.
91.
Montgomery RB, Makary E, Schiffman K et al (2005) Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res 65:650–656PubMed
92.
Disis ML, Schiffman K (2001) Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol 28:12–20PubMedCrossRef
93.
Chapman CJ, Murray A, McElveen JE et al (2008) Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 63:228–233PubMedCrossRef
94.
Yamamoto A, Shimizu E, Ogura T et al (1996) Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients. Int J Cancer 69:283–289PubMedCrossRef
95.
Chen Y, Lin P, Qiu S et al (2007) Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection. Int J Oncol 30:1137–1144PubMed
96.
Ersvaer E, Zhang JY, McCormack E et al (2007) Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. Eur J Haematol 79:210–225PubMedCrossRef
97.
Shi FD, Zhang JY, Liu D et al (2005) Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate 63:252–258PubMedCrossRef
98.
Disis ML, Calenoff E, McLaughlin G et al (1994) Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16–20PubMed
99.
McNeel DG, Nguyen LD, Storer BE et al (2000) Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol 164:1825–1829PubMedCrossRef
100.
Chapman C, Murray A, Chakrabarti J et al (2007) Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 18:868–873PubMedCrossRef
101.
Snijdewint FG, Mensdorff-Pouilly S, Karuntu-Wanamarta AH et al (1999) Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls. Cancer Immunol Immunother 48:47–55PubMedCrossRef
102.
Türeci O, Mack U, Luxemburger U et al (2006) Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett 236:64–71PubMedCrossRef
103.
Nakamura S, Nouso K, Noguchi Y et al (2006) Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J Gastroenterol Hepatol 21:1281–1285PubMedCrossRef
104.
Hogdall EV, Hogdall CK, Blaakaer J et al (2002) P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis. APMIS 110:545–553PubMedCrossRef
105.
Kaur J, Srivastava A, Ralhan R (1997) Serum p53 antibodies in patients with oral lesions: correlation with p53/HSP70 complexes. Int J Cancer 74:609–613PubMedCrossRef
106.
Castelli M, Cianfriglia F, Manieri A et al (2001) Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity. Anticancer Res 21:753–758PubMed
107.
Volkmann M, Muller M, Hofmann WJ et al (1993) The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status. Hepatology 18:559–565PubMed
108.
Coomber D, Hawkins NJ, Clark M et al (1996) Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer. J Cancer Res Clin Oncol 122:757–762PubMedCrossRef
109.
Lubin R, Schlichtholz B, Bengoufa D et al (1993) Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 53:5872–5876PubMed
110.
Angelopoulou K, Stratis M, Diamandis EP (1997) Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer 70:46–51PubMedCrossRef
111.
Creaney J, McLaren BM, Stevenson S et al (2001) p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression. Br J Cancer 84:52–56PubMedCrossRef
112.
Labrecque S, Naor N, Thomson D et al (1993) Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 53:3468PubMed
113.
Selter H, Schmidt G, Villena-Heinsen C et al (1999) Humoral immune response to p21WAF1/CIP1 in tumor patients, non-tumorous patients and healthy blood donors. Cancer Lett 137:151–157PubMedCrossRef
114.
Zhang JY, Zhu W, Imai H et al (2001) De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Exp Immunol 125:3–9PubMedCrossRef
115.
Zhang JY, Chan EK, Peng XX et al (2001) Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol 100:149–156PubMedCrossRef
116.
Yagihashi A, Asanuma K, Kobayashi D et al (2005) Detection of autoantibodies to livin and survivin in Sera from lung cancer patients. Lung Cancer 48:217–221PubMedCrossRef
117.
Yagihashi A, Ohmura T, Asanuma K et al (2005) Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin Chim Acta 362:125–130PubMedCrossRef
118.
Yagihashi A, Asanuma K, Kobayashi D et al (2005) Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma. Autoimmunity 38:445–448PubMedCrossRef
119.
Anderson KS, Ramachandran N, Wong J et al (2008) Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res 7:1490–1499PubMedCrossRef
120.
Soling A, Plugge EM, Schmitz M et al (2007) Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors. Int J Oncol 30:123–128PubMed
Metadata
Title
A systematic review of humoral immune responses against tumor antigens
Authors
Miriam Reuschenbach
Magnus von Knebel Doeberitz
Nicolas Wentzensen
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 10/2009
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-009-0733-4

Other articles of this Issue 10/2009

Cancer Immunology, Immunotherapy 10/2009 Go to the issue

Original Article

Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response

Original Article

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium

Original Article

Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses

Original Article

Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2

Original Article

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

Original Article

Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits